traditionally, xenograft models have been used to study tumors in vivo. However, their utility is reduced by the use of tumor cell lines for implantation. tumorgrafts (tGs; also known as patient-derived xenografts (pDXs)), which involve patient-derived tumor samples, are increasingly recognized as more representative models than traditional xenografts. Furthermore, we showed previously that renal cell carcinoma (rcc) tGs retain the histology, gene expression, Dna copy number alterations, mutations and treatment responsiveness of patient tumors. In skilled hands, implantations require <5 min per mouse, and tGs typically grow to 1 cm in 1-4 months. Here we outline the process of implantation of patient-derived rcc samples into the kidneys of immunodeficient mice, as well as the s.c. implantation for preclinical drug testing, including guidelines for the design and execution of drug trials. tGs have extensive applications besides therapeutic studies and may identify biomarkers and mechanisms of resistance. In addition, they may provide insights into tumor biology.
IntroDuctIon
Kidney cancer is among the ten most common cancers in the United States with an estimated 65,150 new cases and 13,680 deaths in 2013 (ref. 1) . Most malignant kidney tumors are RCCs, which account for >90% of the renal malignancies in adults, with rising incidence 2 . RCC is classified into several subtypes, including clear cell (ccRCC), papillary and chromophobe. Despite recent advances in targeted therapies, metastatic RCC remains largely incurable. One factor hindering drug development is the lack of preclinical models that closely mimic human renal cancer. The inadequacy of current preclinical models is evidenced by the subsequent failure rates of drugs in clinical trials. Less than 20% of the anticancer drugs in development receive approval by the US Food and Drug Administration (FDA) 3 . This illustrates the need for better preclinical models that faithfully recapitulate human cancer.
Xenograft models derived from RCC cell lines have been extensively used to study tumor biology as well as determinants of progression and metastasis [4] [5] [6] . Available RCC cell lines include 786-O, 769-P, A498, Caki-1 and Caki-2. Despite their contributions, studies with cell lines often fail to accurately predict drug responsiveness in patients, possibly owing to the acquisition of mutations during serial culturing 7 . In fact, DNA copy number analyses of RCC cell lines reveal substantially larger numbers of alterations than in patient-derived tumors 8 . In addition, histology and staging information about the tumors giving rise to the cell lines is sometimes incomplete or inaccurate. For example, the origin of Caki-2 cells is controversial 9 . In an attempt to remedy some of these limitations, models have been developed whereby fresh human tumor samples are implanted into immunodeficient mice. These models are known as TGs or PDXs.
TGs have been found to retain the morphology and molecular characteristics of the original tumors [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Models have been generated for several cancer types, including pancreatic, prostate, colon and breast cancers [10] [11] [12] [13] [17] [18] [19] [20] . The implantation of intact tumor fragments into the corresponding organs of immunodeficient rodents may promote growth and preserve the characteristics of the original patient tumors 21 . Orthotopic implantations allow organotypical interactions between tumor cells and the microenvironment in which the tumor arose 22 .
We have developed a RCC model reproducing the characteristics of patient tumors 23 . Herein we report our protocol for the generation of RCC TGs. In addition, we describe the s.c. implantation of these TGs for preclinical drug testing along with guidelines for drug trial design and execution.
Applications of the method
We mainly use this protocol for the preclinical testing of molecularly targeted therapies for RCC. To accurately evaluate drug treatment, TGs must faithfully resemble a patient's tumor. We have shown that our TGs preserve: (i) histology, (ii) gene expression, (iii) DNA copy number alterations, (iv) mutations and (v) treatment responsiveness of renal cancer in humans 23 . Furthermore, paraneoplastic syndromes-conditions that the tumor induces in the host, such as hypercalcemia-are also reproduced in this model 23 .
Our TG model has made possible substantial advances in the understanding of the molecular genetics of ccRCC. Most notably, it facilitated the discovery that BAP1 (encoding BRCA1 associated protein-1) is a two-hit tumor suppressor gene in this cancer type 24 . In patient tissues, contamination from normal human stroma, which dilutes tumor DNA, hinders the detection of mutations (for example, see Fig. 1 ; refs. 24, 25) . Inasmuch as human stroma is replaced by the host in our TGs, Sanger sequencing (with human-specific primers), gene expression microarrays and SNP arrays (for copy number analyses) more accurately reflect what happens in the patient tumor 24 . Thus, analyses in TGs are more sensitive and accurate [23] [24] [25] (for example, see Fig. 1) .
A fundamental problem in oncology is the variability in tumor responsiveness to treatment, which may be due, at least in part, to intra-patient tumor heterogeneity. Tumor heterogeneity has been well documented in ccRCC, a subtype accounting for >70% of all RCCs. Gerlinger et al. 26, 27 recently demonstrated substantial mutation heterogeneity in ccRCC by using a combination of exome sequencing and extensive sampling. By implanting small samples from the patient tumor and sampling multiple areas, TGs provide a means to further dissect tumor heterogeneity and evaluate its implications in drug resistance.
Compared with xenografts derived from established cell lines, which are few in number, the repertoire of TGs is much wider. TGs can be generated from many patients. Most of the samples are obtained from primary tumors and, perhaps expectedly, many do not engraft. Overall, 10-15% of implanted tumor samples engraft and thrive long term. Importantly, the tumors that engraft tend to be the most aggressive and are associated with poor patient outcome 23 . Engraftment rates are substantially higher when metastatic rather than primary tumors are used, indicating that tumors that have acquired the ability to seed distant sites are also more likely to thrive when implanted in another organism 23 . Despite the low engraftment rates, this approach provides a large number and diverse set of lines with different histologies 23 . These TGs allow the evaluation of drugs in clinically relevant models and may assist in drug development 10 . Such a colony may aid in biomarker discovery and could be deployed for personalized medicine.
Approaches similar to the ones outlined herein may be used to generate other TG models. Although there is value in the placement of tumors in their natural (orthotopic) environment, the kidney has long been recognized as an optimal site for tumor engraftment, and this protocol is applicable to the implantation of samples from any tumor type under the kidney capsule.
Limitations
A fundamental problem in oncology is tumor heterogeneity. TGs, which are derived from a small area of the tumor, are unlikely to capture tumor heterogeneity. However, TGs would harbor truncal driver mutations, and if a TG is resistant to a particular drug, the corresponding patient tumor is similarly likely to have resistant clones.
Another limitation of TGs is that the tumors that engraft tend to be most aggressive, and thus they are skewed. We have found that tumors derived from metastatic sites tend to engraft at higher frequencies (50-80%); however, those from primary sites engraft at far lower frequencies (14%) 23 . There is a correlation between the acquisition of metastatic potential by the tumor and engraftment in mice 23 and we believe that many tumors that fail to engraft are tumors that lack the capacity to seed and thrive at distant sites (or in other organisms).
In addition, engraftment rates somewhat unpredictable. Necrotic samples or those with few tumor cells may not engraft at all, and it is challenging to predict timing of growth.
A further limitation is the use of NOD/SCID mice. This strain develops thymic lymphoma (TL) as early as 3-4 months of age (although usually not until 8 months of age). Mice should be monitored for TL symptoms (i.e., panting, bulged eyes and enlarged spleen) at the time of euthanasia ( Supplementary  Fig. 1 ). Malignant lymphocytes can infiltrate the kidney and may be misinterpreted as a TG 12 . For this reason, we examine a sample between each serial passage to ensure the absence of TL cells and to correlate TG histology to the patient histology (Fig. 2) . Although male and female NOD/SCIDs may be used for this procedure, males develop TL at lower rates compared with females and may be preferable for some studies that require a longitudinal follow up.
Experimental design
Collection and manipulation of RCC surgical specimens. In our protocol, RCC human tumor samples are obtained from patients diagnosed with a renal mass greater than 7 cm; multiple, bilateral or recurrent tumors; tumors suspected of invasion on imaging studies; or those associated with regional lymphadenopathy and/or distant metastasis. We adopted these criteria to select for tumors with higher chances of engraftment 23 . Patients provide written informed consent and enroll in a protocol approved by the Institutional Review Board (IRB) that uses otherwise discarded tissue from surgeries. It is important that a clinical pathologist provides the specimens so that diagnosis is not affected and it is ensured that the specimen contains mostly tumor cells. If genetic studies are intended, it is also fitting to collect samples from adjacent normal kidney (or blood) 25 . Handling of human samples should be performed in accordance with Biosafety Level 2 standards. The tumors should be collected in sterile conditions and transported on ice. Ideally, they should be processed as soon as possible after surgical removal to maximize tumor viability and reduce the likelihood of bacterial contamination. In our experience, processing in less than 2 h is adequate, but we have not systematically evaluated how timing affects tumor viability. Processing consists of transferring the patient tumor sample into a Petri dish containing 1% (vol/vol) penicillin-streptomycin (pen-strep) solution dissolved in PBS and cutting fragments for: (i) implantation (15 fragments with a diameter of 2 mm), (ii) long-term preservation in DMSO (30 fragments of 2 mm), (iii) H&E (3-5 mm fragments) and (iv) flash freezing for molecular studies (one or two fragments of 5 mm). We avoid disaggregation or the use of confounding additives, such as Matrigel. This process should be performed under sterile conditions, which are critical to preventing infection in a colony of immunocompromised mice.
Tumor implantation in mice and drug trials. RCC tumor tissues can be implanted either orthotopically or subcutaneously. We use non-obese diabetic/severe combined immunodeficient (NOD/SCID) mice, which are deficient in B and T cells and have impaired NK cells. We typically implant primary patient tumor samples under the renal capsule (orthotopically). Once tumors develop, the TG tissue can be implanted s.c. in the left flank. Subcutaneoous tumors are more suitable for conducting drug trials because they allow accurate measurement of tumor size over time, which facilitates the assessment of drug efficacy. Although we typically conduct drug trials using tissue from early passages (cohorts), and we have limited experience with late cohorts, drug trials with the same TG in both early and late cohorts have shown similar results (data not shown). In our experience, 28 d of treatment provides a suitable time frame for drug trials, particularly when the time frame is sufficient for a more than threefold increase in the tumor volume of vehicle-treated mice.
Ideally, pharmacokinetic (PK) studies are conducted before any drug trials to determine that adequate circulating levels will be achieved and to adjust drug exposures to those expected in humans (if known). Optimally, they are conducted on nontumor-bearing mice of the same strain, age and sex as those used for drug trials. During PK studies, mice are euthanized at different time points after drug administration and blood is collected to measure drug levels using mass spectrometry. Defined amounts of the drug are used as a reference. This information is used to determine the maximal concentration (C max ), drug exposure (AUC, area under the curve) and trough levels (C min ). More detailed information as well as PK studies of two therapies we have investigated using this protocol, sunitinib and sirolimus, can be found elsewhere 23 .
The implantation of tumors into immunodeficient mice should be performed according to the relevant Institutional Animal Care and Use of Committee (IACUC) guidelines. Special care is required while handling animals, including the use of clean personal protective equipment (PPE) and sterile gloves. The preservation of sterile conditions is crucial to preventing bacterial or fungal infections. After implantation, mice should be monitored daily and, if orthotopically implanted, palpated weekly. In particular, mice implanted with tumors from patients with paraneoplastic hypercalcemia should be monitored very closely, as paraneoplastic hypercalcemia also develops in mice and the mice may develop seizures and die unexpectedly.
Database maintenance. A crucial aspect of building a TG colony is the development of a database that captures patient and TG information. We use a password-protected excel file that can only be accessed by pertinent personnel associated with the IRBapproved protocol. When approved by the IRB, it is most helpful to retain identifiers, which allow going back to the medical record when necessary. For instance, when we discovered that some mice were dying from paraneoplastic hypercalcemia, we were able to go back and determine that the patients who had donated the tumors had also experienced the same paraneoplastic syndrome.
Our database is composed of four main tabs: 'surgeries', 'modified', 'tumorgrafts' and 'sacrificed tumorgrafts' (Supplementary Table 1 ; version provided is simplified). The surgeries tab lists the patients at our institution with planned surgeries for the removal of primary or metastatic RCC. Although we only implant tissue from patients meeting the criteria outlined in the methods, tissue is routinely collected from all consenting patients undergoing surgery. The surgeries tab also captures patient demographics (i.e., age, gender, race and family history of RCC) as well as radiology and pathology information. This tab is color-coded to identify patients from whom tissue was collected and those whose tissue was implanted (black for non-implanted and blue for implanted). The information for all patients whose tumors are implanted (blue) is then copied onto to the modified tab. The modified tab includes most of the information in the surgeries tab, plus additional clinical data, including actual procedure performed, and information about the TGs. The tumorgraft tab contains information for all currently implanted mice in the colony such as TG number, cohort, ear tag number and the presence of a palpable tumor. This tab is essential for tracking tumor growth and to determine when each tumor should be passaged for each TG line. Finally, the sacrificed tab includes all the mice that were implanted, but which are not currently alive. Once a mouse is euthanized, the information from the tumorgraft tab is transferred to this tab, which includes additional information obtained at the time of death (i.e., tumor size, number of mice passaged, presence of enlarged thymus and tissue storage). It is critical that such a database be updated in real time in order to avoid errors. Human RCC tissue ! cautIon All tissue handling should be performed in a Biosafety Level 2 hood. Be careful when working with human tissue; always use gloves and avoid direct skin contact. Assume patients may have been infected with HIV or other highly transmissible organisms. We do not process samples that are known to carry infections.  crItIcal All work with human material should be accompanied by an informed consent from the donor. NOD/SCID mice, 4-8 weeks old. We have also used NOD/SCID γc-deficient mice, but we have limited experience with this strain ! cautIon All experiments should be performed in accordance with institutional and governmental guidelines and regulations.  crItIcal Always handle mice under a sterile hood and with sterile instruments. Change gloves often if non-sterile objects have been handled, and spray them with NPD. Never open cages outside of the hood or expose animals to the outside environment. Our animal room is kept at 72 °F (22 °C 1% (vol/vol) pen-strep solution in PBS Add 5 ml of pen-strep solution to a 500-ml bottle of sterile PBS. Once prepared, it can be stored at 4 °C for up to 4 weeks. 10% (vol/vol) DMSO/HBSS Add 50 ml of DMSO to a 450 ml bottle of sterile HBSS. Mix the solution and filter it using a 0.22-µm filter. Once prepared, it can be stored at 4 °C. ! cautIon If this solution gets contaminated it will have devastating consequences, so it is recommended that it be handled with particular care and replaced every 3 months. 70% (vol/vol) ethyl alcohol Mix seven parts of alcohol with three parts of double-filtered water and transfer the solution to a spray bottle. It can be stored at room temperature indefinitely. The room temperature of our laboratory and the room where solutions are stored is set to 69 °F (21 °C). Buprenorphine solution Transfer 1 ml of buprenorphine (0.3 mg/ml) to a sterile 50-ml conical tube. Bring the volume up to 20 ml by adding sterile PBS. Solution can be stored at room temperature for up to 6 months. Once you have determined the number of mice to implant, add an appropriate amount of buprenorphine solution (100 µl per mouse) in a 1-ml syringe with a 27-gauge needle before beginning the procedure.  crItIcal Preparing this solution before the surgical procedure will ensure that you have the buprenorphine solution ready to inject before the mouse wakes up from anesthesia. EDTA solution Dissolve 7.3 g of EDTA into ~40 ml of sterilized water by placing it on a rocker until the crystals dissolve. Check the pH using a calibrated pH meter. Adjust the pH to 8.0 using a small amount of NaOH, and then bring the volume up to 50 ml by adding more sterile water. Filter the solution through a 0.22-µm filter into a fresh 50-ml conical tube. EDTA can be stored at room temperature until crystals start to precipitate out of solution. NPD solution Dilute 0.5 fluid ounces of stock NPD solution (14.8 ml) into a gallon of water (3,785 ml). It can be stored at room temperature for up to 2 weeks. Allow 10 min of contact time to disinfect. ! cautIon Avoid direct contact with skin and eyes. EQUIPMENT SETUP Fresh tissue processing Time from sample removal from the patient to tissue processing should not exceed 2 h. This timing is crucial, as tissue will quickly deteriorate after blood supply is cut off. Autoclave all instruments in 
2|
Place the tissue in a tube containing ~10 ml of HBSS solution and place it on ice. Proceed to Step 3 as soon as possible.  crItIcal step Keep the tissue moist and cold to preserve it until processing.  crItIcal step Time from sample removal from the patient to tissue processing should not exceed 2 h. This timing is critical, as tissue will quickly deteriorate after blood supply is cut off.
3|
Place the tissue in a sterile hood. Pick up the tissue using a pair of sterile autoclaved forceps and transfer to a sterile p150 dish containing ~10 ml of sterile PBS with 1% (vol/vol) pen-strep solution in PBS.
4| By using sterile forceps and a razor blade, remove any tissue that appears normal or necrotic, or which is clearly heterogeneous. Tumor tissue is fleshy, whereas necrotic tissue is often yellow and breaks apart easily when touched.  crItIcal step Often the tissue available may not be large enough to store for all purposes outlined below (i.e., flash frozen, formalin and DMSO samples). Prioritize tissue processing according to your specific project needs.
5| Cut a 3-5 mm fragment to place in a vial (we typically use a screw-cap cryovial) with formalin. Perform histological analysis of this sample as described in Box 1 to confirm the presence of tumor cells (Fig. 3) . ! cautIon Be careful not to expose your skin to formalin.
6|
Cut ~45 fragments ~2 mm in diameter from the remaining tumor tissue. Split 15 fragments into three 1.5-ml cryovials. Label the cryovials with 'TG ID' and 'for implantation', and place them on ice (be sure to add ~100 µl of sterile 1% (vol/vol) pen-strep solution in PBS to the tube to keep the tissue moist).  crItIcal step No identifiers that can be traced back to the patient should be on any tubes, such as name, initials or date of birth. Do not allow the tissue to become dry.  crItIcal step Do not implant any fragments that float as this may be fat.
7|
Label two additional cryovials with 'TG ID' and 'DMSO' and place 15 tumor fragments in each. Add 1 ml of cold 10% (vol/vol) DMSO/HBSS from an aliquot to the tissue in each cryovial, and then transfer the cryovials to wet ice.  crItIcal step DMSO solution must be kept cold at all times to prevent damage to cells.  crItIcal step Samples should be transferred to a −80 °C freezer within 10 min of adding the DMSO solution. Plan the addition of DMSO solution accordingly.
8|
Place any remaining tissue in a 1.5-ml cryovial. Label the vial with 'TG ID' and 'flash frozen' . Freeze the flash frozen sample by placing it in liquid nitrogen; transfer it to −80 °C for permanent storage. This tissue can be used for protein or genetic analysis as previously described 25 . 11| Shave off the fur from its back (Fig. 4b) . Make sure that the shaver has a sharp blade. ! cautIon Do not apply too much pressure while shaving, as this may harm the skin. Mouse skin should not be injured while shaving.
9|

12|
Apply iodine and let it be absorbed into the skin, and then wipe with an alcohol pad.
13|
Lift back the skin with the 'external' curved forceps and create a 1-cm incision by cutting along the spine with 'external' scissors (Fig. 4b) .
14|
With the aid of the 'internal' pair of scissors, blunt dissect toward the left hind leg (Fig. 4c) . Introduce the
Box 1 | Processing of formalin-fixed tissue to confirm the presence of tumor cells
• tIMInG 30-60 h, including incubation time 15| Place the mouse on its side and view the location of the kidney through the body wall.
16|
With 'internal' instruments, make a small transverse incision in the body wall slightly longer than the long axis of the kidney, ~1 cm.
? trouBlesHootInG 17| Apply pressure on both sides of the abdomen with your forefinger and thumb and exteriorize the kidney (Fig. 4d) .
If you are working with female mice, removal of the kidney is done by gently pulling on the fat pad at the base, which also contains the ovary. ! cautIon Make sure not to damage the ovaries-this will cause bleeding. Allow the kidney to rest on the body wall.
18| Make a 2-4 mm incision (dorsal, caudal to rostral) in the capsule with curved spring-loaded scissors. Create a pocket between the capsule and the underlying parenchyma (Fig. 4e) . ! cautIon Do not damage the parenchyma, which will bleed if damaged.  crItIcal step Keep the scissors as close to the renal capsule as possible while also being careful not to rip the capsule.
19|
Implant two or three pieces of 2 × 2 × 2 mm tumor tissue (from Step 6, one at a time) into the pocket under the capsule with a pair of fine forceps. The capsule should appear transparent and grafts within the kidney should be visible (Fig. 4f,g ).  crItIcal step Note that if the tissue is not visible under the capsule, engraftment rates may be reduced. ? trouBlesHootInG 20| When grafting is complete, gently ease the kidney back into the body cavity. Suture the body wall with absorbable suture. Apply two continuous stitches and tie the loose ends with two knots (Fig. 4h) .
21|
Apply staples, making sure that the skin is completely closed (Fig. 4i) .  crItIcal step Do not staple the body wall and skin together as this will cause a painful swelling.
22| Spray the back of the neck with 70% (vol/vol) ethanol. Pinch the scruff on the back of the neck; this will make a pocket between folds of the pinched skin. Insert the needle and inject 100 µl of buprenorphine dilution s.c. (Fig. 4j,k) .  crItIcal step Administer buprenorphine after the surgery and the following morning. Record buprenorphine use in a ledger.  crItIcal step Buprenorphine is a controlled substance and its use must be meticulously monitored and recorded according to IACUC policy. 23| By using the ear tag applicator, grab the ear tag from the sleeve. Apply the ear tag to the mouse before it wakes up.
24|
Monitor the mice every 2 d after surgery until the removal of staples. Staple removal can be done 7-14 d after the surgery.
25|
After removing the staples, monitor tumor growth by palpation at least weekly. Tumors may develop 14-180 d from surgery. Once a tumor reaches at least ~7 mm by palpation, proceed to the next step to passage to subsequent cohorts. ! cautIon Do not let the tumors exceed 1-1.5 cm. Large tumors are painful to the mice and will cause death.
Harvesting and passaging tissue • tIMInG 15-30 min per mouse (in skilled hands, 5 min per mouse) 26| Anesthetize the tumor-bearing mouse by using a 50-ml conical tube with paper towel fragments soaked in isoflurane. Do not anesthetize mice by using the induction chamber used for implantation.  crItIcal step We avoid using the induction chamber for terminal procedures in an effort to minimize the infection of mice subjected to survival surgeries.
27| Check the level of anesthesia by toe-pinching. Once the mouse no longer responds to toe-pinching, if desired, collect blood by cardiac puncture (Fig. 5) . Blood may be useful for cell counts, chemistries, metabolic studies and the identification of biomarkers. To collect blood, use a 1 ml syringe with a 25-gauge needle to draw ~10 µl of EDTA solution. Lay the mouse supine and spray its chest and abdomen with 70% (vol/vol) ethanol. Locate the sternum and insert the needle directly below and parallel to the sternum on the left side ~30 degrees from the horizontal to a depth of ~1 cm. Slowly draw up to 1 ml of blood into the syringe.  crItIcal step To ensure a proper blood draw, the process should be performed slowly and carefully. Multiple attempts to draw blood may cause hemolysis. Expel the blood from the syringe into a 1.5-ml tube and place the tube on ice until the procedure is finished. ? trouBlesHootInG
28|
After any blood has been collected, dislocate the cervical spine to ensure death by placing your index finger and thumb behind the skull and pulling the body by the base of the tail. You will feel the spine separating from the head.  crItIcal step Death must be ensured before opening the mouse to extract the tumor.
29|
Place the mouse in a supine position and spray abdomen with 70% (vol/vol) ethanol. Use forceps and scissors to make a midline incision down the body to expose the organs.
30|
Use a new sterile set of instruments to locate the left kidney with the growing tumor (Fig. 5b) . ! cautIon Be careful not to cut the bowel when extracting the tumor-bearing kidney, as this may expose it to bacteria.
31|
Place the kidney with the tumor in a p150 dish containing ~10 ml of sterile PBS containing 1% (vol/vol) pen-strep solution in PBS. Bisect the kidney and remove all normal kidney from the specimen (Fig. 4c,d ).  crItIcal step Do not implant normal kidney into subsequent cohorts of mice.
32|
Either perform orthotopic passaging by repeating Steps 10-32 (orthotopic passaging can be continued indefinitely), proceed to s.c. implantation (Step 34) for a drug trial or store the tissue. Tissue can also be implanted from the sample stored in DMSO at Step 7 if required; to do this, follow the guidelines in Box 2.
33| Once all surgical procedures have been completed, spin the blood collected at Step 27 at 3,000g for 10 min. Collect plasma and transfer it to a new cryovial. Store it at −80 °C indefinitely.
Implantation for drug trials • tIMInG 2-3 min per mouse 34| Take fresh TG tissue after collection and cut 4 × 4 × 4 mm fragments to be implanted s.c. into as many mice as needed for a drug trial.  crItIcal step If more than one mouse's tumor is required for drug trial implantation, it is best to select mice in the same cohort (derived from the same initial patient tumor fragment) with a similar tumor size. This will reduce differences in tumor growth rates. ? trouBlesHootInG 35| Perform Steps 10-14 on a mouse.
36|
With the 'internal' pair of scissors, separate the dermis from the body wall. Do not open the scissors; insert them to make a tunnel underneath the skin toward the left hind leg (Fig. 6a) .  crItIcal step Opening the scissors will allow the tissue to freely move once inserted. This can cause difficulties in measuring the tumors.
37| Pick up a 4 × 4 × 4 mm tissue fragment from
Step 34 with the 'internal' straight forceps and place it underneath the skin (Fig. 6b) .  crItIcal step Make sure that you avoid any contact between tumor fragment and the mouse's skin as this may introduce bacteria.
38| By using an 'external' set of curved forceps, hold the site of incision. With another set of 'external' forceps, push tumor down the flank of the mouse on the outside of the skin toward the hind leg (Fig. 6c) .  crItIcal step Ensure that the tumor fragment is far away from the incision site to prevent it from being stapled to the skin.
39|
Apply staples making sure that the skin is completely closed.
40|
Administer 100 µl of buprenorphine immediately after surgery. It is not necessary to administer another dose the following day. 
Box 2 | Implantation from DMSO • tIMInG 5-30 min per mouse
If a line has been electively frozen (DMSO), the following steps can be followed to reimplant the tumor from the sample stored in DMSO at Step 7.
1. Keep the tube frozen until you are ready to implant tissue.  crItIcal step Minimize the time for which the tissue is at room temperature while on DMSO, as this will reduce viability and decrease the chances of engraftment. 2. Thaw the DMSO tube until ~80% of the solution has melted and place the tissue in a p150 Petri dish containing ~10 ml of 1% (vol/vol) pen-strep solution in PBS to rinse. Transfer the fragments to another Petri dish containing ~10 ml of 1% (vol/vol) pen-strep solution in PBS.
3. Implant the tissue into mice as described in Steps 10-25 of the main PROCEDURE.
tumor measurements for drug trials • tIMInG 2-3 min per mouse 42| Pick up the mouse by holding its tail. To do this, place the mouse on the wire bars of the cage lid to get a good grip. Hold the mouse's tail with your dominant hand. With your non-dominant hand, cup the mouse. By using the thumb and first finger, hold the scruff on the back of the neck behind the ears firmly. Tuck the tail between your last two fingers, so that the spine of the mouse is resting next to your knuckles. Once the mouse is securely restrained in your non-dominant hand, pick the mouse up.
43|
With the help of calipers, measure the largest length of the tumor, then the largest perpendicular width and finally the depth. Multiply these together to get estimated volume. This formula (V = length × width × depth) minimizes giving excessive weight to a particular dimension, which can introduce a bias.
44|
Repeat Steps 42 and 43 twice a week until the volumes reach 300-500 mm 3 . When tumors reach this volume, proceed to the next step and allocate the mice into treatment arms.  crItIcal step The tumors must be allowed to reach at least 300 mm 3 to ensure that the tumors are growing. Failure to do this may lead to lack of tumor growth during the trial period, and this could erroneously be interpreted as suppression of growth by the administered drug. In addition, a vehicle control should always be included in drug trials.
allocation into treatment groups • tIMInG variable, depending on project needs 45| Separate mice into treatment groups on the basis of the following criteria: tumor volume, growth rate and mouse weight. First, sort the mice by tumor volume. Next, sort the mice by tumor growth rates relative to the first measurement. This may be accomplished in an Excel file by sorting the mice according to tumor fold change with respect to the first tumor measurement.  crItIcal step It is important to visually inspect the tumor growth rates, as tumors with a plateau phase may be unsuitable. Finally, obtain the weights of the mice and sort the mice according to weight.
46|
Distribute the mice such that each treatment group is as similar as possible according to the aforementioned criteria.  crItIcal step If treatment groups are not similar, the data gathered may be uninterpretable or biased.
47|
Tag and arrange to house mice in separate cages according to treatment groups.  crItIcal step This will minimize the chances of administering the wrong treatment.  crItIcal step If mice are too old, and, in particular, if they are male, they will fight; females are thus preferable for drug trials.
48|
Weigh each mouse and treat it with an appropriate volume of drug or vehicle (for controls). Monitor mice regularly and take measurements twice weekly.
49|
Treat the mice for 28 d, with route and intervals as determined by PK analyses. Weigh the mice once per week during the treatment period and adjust drug volume accordingly. In our experience, treatment for 28 d is suitable, particularly when that time frame is sufficient for a greater than threefold increase in the tumor volume in vehicle-treated mice. However, for slower growing tumors, longer drug trials may be required. Proceed to the next step (drug trial termination) at an appropriate time point after the last drug treatment, depending on the information you wish to gain from the final samples obtained. We euthanize mice 2-4 h after the last drug treatment.  crItIcal step This is done to ensure high drug levels in tissue and plasma. Alternatively, mice can be killed at the trough (1 h before the next drug dose is scheduled).  crItIcal step 28 d of drug treatment should provide an adequate dynamic range to evaluate therapeutic effects. 51| Perform a final tumor measurement through the skin, as described in Steps 42 and 43.
52| Anesthetize the mice with isoflurane, perform cardiac puncture and kill them (as outlined in Steps 26-28); process blood as described in Step 33.
53|
If desired, take a digital picture of the mouse lying on its abdomen with the tumor area visible (Fig. 7) .
54|
Carefully resect the tumor from the s.c. space. Place the tumor on a p150 dish, on top of a white background above a ruler. Write the ear tag number and treatment group below the tumor on the white paper. Be sure that the tumor is aligned with the 0 cm mark so that the pictures taken are consistent across the treatment groups. Take a picture with the tumor and the ear tag and treatment group visible.
55|
Record tumor dimensions of resected tumor and also tumor weights.
56|
Retain tumor tissue as appropriate for any further analysis you wish to perform. We cut tumors in half and place them in two cryovials. We freeze one in liquid nitrogen and add formalin to the other. The frozen tissue can be used to test for drug levels in the tissue and for protein analyses by western blotting, and the fixed tissue can be used for histological studies.
? trouBlesHootInG Troubleshooting advice can be found in table 1.
• tIMInG
Step 1, Selecting tissue from qualifying patients: variable; depends on the number of patients Implant three or four mice before implanting a large number for a drug trial in order to assess tumor growth s.c. As an alternative, consider implanting orthotopically and measuring the tumor growth with ultrasound or, preferably, MRI
